A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m(2) (Dralitem(®) vs. Temodal(®) Capsules) in Patients with Primary Tumors of the Central Nervous System Under Fasting Conditions

BACKGROUND: Temozolomide is an antineoplastic agent of proven efficacy against high-grade gliomas. PURPOSE: The objective of this crossover, single-dose, bioequivalence study was to compare the rate and extent of absorption of oral temozolomide after administration of the study product (Dralitem(®),...

Descripción completa

Detalles Bibliográficos
Autores principales: Muggeri, Alejandro, Vago, Miguel, Pérez, Sebastián, Rubio, Marcelo, González, Cecilia, Magariños, Cristian, Rosenberg, Mónica, Costa, Fernando, Pérez-Lloret, Santiago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629139/
https://www.ncbi.nlm.nih.gov/pubmed/28756607
http://dx.doi.org/10.1007/s40268-017-0199-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629139/
https://www.ncbi.nlm.nih.gov/pubmed/28756607
http://dx.doi.org/10.1007/s40268-017-0199-3

Ejemplares similares